- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Andaris files ultrasound contrast IND
Ultrasound contrast developer Andaris of Nottingham, UK, has filed an investigational new drug (IND) application with the Food and Drug Administration to begin phase II clinical trials for cardiac indications of its Quantison agent. The application
Ultrasound contrast developer Andaris of Nottingham, UK, has filed an investigational new drug (IND) application with the Food and Drug Administration to begin phase II clinical trials for cardiac indications of its Quantison agent. The application covers the use of Quantison for left ventricular opacification as well as myocardial perfusion indications. Quantison consists of air-filled albumin microcapsules developed for intravenous imaging (SCAN 2/5/97).
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.
